SLKDT downregulated PPAR‐γ and C/EBP‐α mRNA expressions and upregulated PPAR‐α, CPT‐1, LPL, and CYP7A1 mRNA expressions to reduce adipocyte differentiation and fat accumulation, accelerate fat oxidation, and improve dyslipidemia, then inhibit the immune response and alleviate liver injury. The gene discussed is CEBPA; the disease is metabolic syndrome.